BT 7455
Alternative Names: BT-7455Latest Information Update: 19 Jun 2024
At a glance
- Originator Bicycle Therapeutics
- Class Antineoplastics; Bicyclic peptides; Small molecules
- Mechanism of Action CD137 antigen agonists; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2024 Efficacy and adverse events data from a preclinical trial in Cancer presented at 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 31 Dec 2023 BT 7455 is still in preclinical trials for Cancer in United Kingdom
- 14 Apr 2023 Pharmacodynamics and pharmacokinetics data from preclinical studies in Cancer presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)